Supernus Pharmaceuticals Cash on Hand 2011-2024 | SUPN
Supernus Pharmaceuticals cash on hand from 2011 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Supernus Pharmaceuticals Annual Cash on Hand
(Millions of US $) |
| 2023 |
$255 |
| 2022 |
$461 |
| 2021 |
$340 |
| 2020 |
$423 |
| 2019 |
$347 |
| 2018 |
$356 |
| 2017 |
$140 |
| 2016 |
$90 |
| 2015 |
$62 |
| 2014 |
$74 |
| 2013 |
$82 |
| 2012 |
$89 |
| 2011 |
$49 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Cash on Hand
(Millions of US $) |
| 2024-06-30 |
$347 |
| 2024-03-31 |
$298 |
| 2023-12-31 |
$255 |
| 2023-09-30 |
$200 |
| 2023-06-30 |
$152 |
| 2023-03-31 |
$632 |
| 2022-12-31 |
$461 |
| 2022-09-30 |
$392 |
| 2022-06-30 |
$361 |
| 2022-03-31 |
$312 |
| 2021-12-31 |
$340 |
| 2021-09-30 |
$444 |
| 2021-06-30 |
$410 |
| 2021-03-31 |
$391 |
| 2020-12-31 |
$423 |
| 2020-09-30 |
$352 |
| 2020-06-30 |
$375 |
| 2020-03-31 |
$401 |
| 2019-12-31 |
$347 |
| 2019-09-30 |
$297 |
| 2019-06-30 |
$259 |
| 2019-03-31 |
$293 |
| 2018-12-31 |
$356 |
| 2018-09-30 |
$280 |
| 2018-06-30 |
$174 |
| 2018-03-31 |
$490 |
| 2017-12-31 |
$140 |
| 2017-09-30 |
$115 |
| 2017-06-30 |
$93 |
| 2017-03-31 |
$87 |
| 2016-12-31 |
$90 |
| 2016-09-30 |
$80 |
| 2016-06-30 |
$60 |
| 2016-03-31 |
$45 |
| 2015-12-31 |
$62 |
| 2015-09-30 |
$58 |
| 2015-06-30 |
$70 |
| 2015-03-31 |
$65 |
| 2014-12-31 |
$74 |
| 2014-09-30 |
$73 |
| 2014-06-30 |
$47 |
| 2014-03-31 |
$59 |
| 2013-12-31 |
$82 |
| 2013-09-30 |
$87 |
| 2013-06-30 |
$103 |
| 2013-03-31 |
$70 |
| 2012-12-31 |
$89 |
| 2012-09-30 |
$61 |
| 2012-06-30 |
$77 |
| 2012-03-31 |
$38 |
| 2011-12-31 |
$49 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.872B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
